Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines
作者:T T Kung、Y Crawley、B Luo、S Young、W Kreutner、R W Chapman
DOI:10.1038/sj.bjp.0703308
日期:2000.5
This study investigates the role of adrenal‐derived catecholamines and corticosterone on the inhibition by rolipram, a phosphodiesterase (PDE)‐4 inhibitor, of pulmonary eosinophilia and airway hyperresponsiveness (AHR) in allergic mice.
The following experimental groups were studied in mice sensitized and challenged with ovalbumin (OVA): normal, adrenalectomized, propranolol (β‐adrenoceptor antagonist) and metyrapone (corticosterone synthesis inhibitor) treated. These interventions were studied both in the absence and in the presence of rolipram. Eosinophil numbers in the bronchoalveolar lavage (BAL) and AHR to methacholine were measured 24 h after OVA challenge.
Treatment of sensitized mice with rolipram (0.3–10 mg kg−1, p.o.), inhibited pulmonary eosinophilia and the AHR to methacholine in OVA‐challenged mice.
Adrenalectomy increased the number of eosinophils in the BAL of OVA‐challenged mice but had no effect on AHR to methacholine. Adrenalectomy attenuated both the rolipram‐induced inhibition of BAL eosinophilia and AHR to methacholine in OVA challenged mice. Propranolol (10 mg kg−1, p.o.) had no effect on the inhibition of eosinophilia by rolipram but attenuated the inhibition of AHR to methacholine in OVA challenged mice. On the other hand, metyrapone (10 mg kg−1, p.o.) attenuated the inhibition of eosinophilia by rolipram but had no effect on the inhibition of AHR to methacholine in OVA challenged mice. Metyrapone‐treatment alone increased the number of eosinophils in the BAL of OVA‐challenged mice.
These results identify an important role for adrenal‐derived catecholamines and corticosterone on the inhibition of pulmonary eosinophilia and AHR by rolipram in allergic mice.
British Journal of Pharmacology (2000) 130, 457–463; doi:10.1038/sj.bjp.0703308
本研究探讨了肾上腺来源的儿茶酚胺和皮质酮在磷酸二酯酶(PDE)-4抑制剂罗吡尼兰对过敏小鼠的肺部嗜酸性粒细胞增多和气道高反应性(AHR)抑制中的作用。
我们对用卵清蛋白(OVA)致敏并激发的小鼠进行了研究,分为以下实验组:正常组、肾上腺切除组、普萘洛尔(β-肾上腺素能受体拮抗剂)治疗组和美替拉酮(皮质酮合成抑制剂)治疗组。这些干预措施在有无罗吡尼兰的情况下均进行了研究。OVA激发24小时后测量支气管肺泡灌洗液(BAL)中的嗜酸性粒细胞数量以及对甲酰胆碱的气道高反应性。
用罗吡尼兰(0.3-10 mg/kg,口服)治疗OVA致敏的小鼠,抑制了肺部嗜酸性粒细胞增多,并降低OVA激发小鼠对甲酰胆碱的气道高反应性。
肾上腺切除增加了OVA激发小鼠BAL中的嗜酸性粒细胞数量,但对甲酰胆碱引起的气道高反应性无影响。肾上腺切除削弱了罗吡尼兰对OVA激发小鼠BAL嗜酸性粒细胞增多及对甲酰胆碱引起的气道高反应性的抑制作用。普萘洛尔(10 mg/kg,口服)对罗吡尼兰抑制嗜酸性粒细胞增多的效果无影响,但削弱了其对OVA激发小鼠甲酰胆碱引起的气道高反应性的抑制作用。另一方面,美替拉酮(10 mg/kg,口服)削弱了罗吡尼兰抑制OVA激发小鼠肺部嗜酸性粒细胞增多的效果,但对罗吡尼兰抑制甲酰胆碱引起的气道高反应性无影响。单独使用美替拉酮治疗增加了OVA激发小鼠BAL中的嗜酸性粒细胞数量。
这些结果表明,肾上腺来源的儿茶酚胺和皮质酮在罗吡尼兰对过敏小鼠肺部嗜酸性粒细胞增多和AHR抑制中发挥重要作用。
*英国药理学杂志*(2000),130, 457–463; doi:10.1038/sj.bjp.0703308